Zenas BioPharma(ZBIO)
WALTHAM, MAPharmaceutical
Focus: Zenas BioPharma is a publicly traded immunology-focused biotech founded in 2020, headquartered in Waltham, MA, developing immune-based therapies across neurology, immunology, and endocrinology. The company is in early-to-mid stage development with a robust pipeline but minimal current revenue.
Profile data last refreshed 17h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
12+1 this month
Stable — net +1 jobs in 30d
6 added, 5 removed. Backfill posture.
Should You Work at Zenas BioPharma?
AI assessmentZenas is a high-risk, high-upside opportunity best suited for scientists willing to bet on pipeline success; cash runway and Phase 3 catalysts provide 2–3 year runway, but commercial execution remains unproven.
Why Work Here
- Three Phase 3 programs in immunology (Obexelimab for IgG4-RD, Orelabrutinib for MS) provide near-term catalysts and clinical validation opportunities.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$5M
Pipeline & Clinical Trials
ZB001 for injection
Healthy VolunteersClinical Trials (1)
NCT05542303A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects
Phase 1Help build intelligence for Zenas BioPharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.